Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;106(2):391-409.
doi: 10.1177/13872877251342273. Epub 2025 Jul 1.

The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease

Affiliations
Review

The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease

Yuhan Nong et al. J Alzheimers Dis. 2025 Jul.

Abstract

The accumulation of amyloid-β (Aβ) peptides is a hallmark of Alzheimer's disease (AD). Central to AD pathology is the production of Aβ peptides through the amyloidogenic processing of amyloid-β protein precursor (AβPP) by β-secretase (BACE-1) and γ-secretase. Recent studies have shifted focus from Aβ plaque deposits to the more toxic soluble Aβ oligomers. One significant way in which Aβ peptides impair neuronal information processing is by influencing neurotransmitter receptor function. These receptors, including adrenergic, acetylcholine, dopamine, 5-HT, glutamate, and gamma-aminobutyric acid (GABA) receptors, play a crucial role in regulating synaptic transmission, which underlies perceptual and cognitive functions. This review explores how Aβ interacts with these key neurotransmitter receptors and how these interactions contribute to neural dysfunction in AD. Moreover, we examine how agonists and antagonists of these receptors influence Aβ pathology, offering new perspectives on potential therapeutic strategies to curb AD progression effectively and improve patients' quality of life.

Keywords: 5HT; Alzheimer's disease; GABA; acetylcholine; amyloid-β; dopamine; glutamate; neurotransmitter; norepinephrine.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsQ.W. is the co-founder of Sharper Sense, a company developing methods of enhancing sensory processing with neural interfaces.

Similar articles

References

    1. Zhao J, Liu X, Xia W, et al. Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease. Front Mol Neurosci 2020; 13: 137. - PMC - PubMed
    1. Anderson JP, Esch FS, Keim PS, et al. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neuroscience letters 1991; 128: 126–128. - PubMed
    1. Wilson CA, Doms RW and Lee VM. Intracellular APP processing and Aβ production in Alzheimer disease. Journal of neuropathology and experimental neurology 1999; 58: 787–794. - PubMed
    1. Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. Journal of Biological Chemistry 1992; 267: 546–554. - PubMed
    1. Sherrington R, Rogaev E, Liang Ya, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995; 375: 754–760. - PubMed

MeSH terms

Substances

LinkOut - more resources